T-cell prolymphocytic leukaemia: lines of therapy

Cancer page →

2 standard-of-care settings across 2 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

Line	All comers
Second line	1
Other settings	1

Second line

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Relapsed	Venetoclax with or without ibrutinib; trials such as the MDM2 inhibitor study linked here.	VenetoclaxIbrutinibA Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL		95

Other settings

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Active disease	Intravenous alemtuzumab to best response, then allogeneic or autologous stem cell transplant in fit patients.	AlemtuzumabAllogeneic stem cell transplant (allo-SCT)Leukaemia (all types)		53

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.